Dermatologists treating hair disorders in younger children have long operated without formal guidance — until now. An international expert panel has published a consensus statement in JAMA Dermatology outlining how to safely prescribe low-dose oral minoxidil for children aged 4–12 years. The six-step protocol covers four key indications: hair follicle miniaturization, hair cycle disorders, hair shaft disorders, and adjunctive therapy for certain scarring alopecias, along with clear contraindications like pheochromocytoma or a history of pericardial effusion.

The panel, which used a modified Delphi process across three survey rounds with ~50 experts, also weighed in on when oral therapy may be preferable to topical — think large-area diffuse hair loss, sensory sensitivities, or even the risk of topical minoxidil toxicity to household pets. Importantly, the consensus does not call for blanket baseline testing; instead, monitoring should be tailored to each child's medical history and risk profile.

Key Takeaways:

• Indications for hair follicle miniaturization and hair cycle abnormalities reached 100% consensus; adjunctive therapy hit 98%
• 96% of panelists agreed low-dose oral minoxidil is safe for children aged 4–12
• No consensus was reached for children under 4 years due to limited data and pharmacokinetic concerns
• The statement is a framework for decision-making, not an evidence-based guideline — prospective trials are still needed

Why it matters: This consensus gives clinicians a much-needed, expert-backed starting point for a patient population that has historically been excluded from prescribing guidance, helping standardize care while prospective pediatric evidence catches up.